Regarding data exchange, the Aragon Ethics Committee approved this research without considering the option of data sharing. The data contains sensitive clinical information about the patient, so there are ethical and legal restrictions to sharing the data set. The data are part of the MULTIPAP study and can be requested by contacting the Aragon Ethics Committee at the email address <ceica@aragon.es>; for the request of data you can also contact the Primary Care Management of Madrid at the email address <gap@salud.madrid.org>; and by contacting the Technical Direction of Teaching and Research at the email address <dtdei@salud.madrid.org> The MULTIPAP Group may establish future collaborations with other groups based on the same data. The main researchers of the project will be contacted (Alexandra Prados-Torres at <sprados.iacs@aragon.es>; Daniel Prados-Torres at <uand.prados.sspa@juntadeandalucia.es>; and Isabel del Cura at <isabel.cura@salud.madrid.org>). However, each new project based on these data must be previously submitted to CEICA for approval.

Introduction {#sec006}
============

Multimorbidity, defined by the WHO as the coexistence of two or more chronic illnesses in a person \[[@pone.0237186.ref001]\], is a growing phenomenon. It describes the complex interaction in a patient of several co-existing diseases. It has become a health problem and an international health challenge \[[@pone.0237186.ref002]\] resulting from increased life expectancy and non-transmittable disease rates, among other factors.

Patients with multimorbidity usually present polypharmacy, defined as the simultaneous use of several medicines\[[@pone.0237186.ref003]\]. Data from the USA National Health Survey yielded a prevalence of polypharmacy of 39% in the population aged over 65 years \[[@pone.0237186.ref004]\]. An European study, with medication dispensing data for 310,000 adults, observed that the proportion of patients with ≥5 drugs dispensed doubled, reaching 20.8% in the 1995--2014 period\[[@pone.0237186.ref005]\]. In the National Health Survey in Spain in 2017, in this same age range, 27.7% of respondents reported consuming at least 5 or more drugs or pharmaceutical preparations \[[@pone.0237186.ref006]\].

Polypharmacy entails a greater risk for potentially inappropriate prescribing (PIP), which is defined as "the prescribing of medications that should generally be avoided in persons 65 years or older because they are either ineffective or they pose unnecessarily high risk where a safer alternative is available" \[[@pone.0237186.ref007]\]. Optimization and the appropriateness of prescriptions in this population has become a global public health problem.

To analyse potentially inappropriate prescriptions in primary care complex patients, explicit and implicit methods have been proposed \[[@pone.0237186.ref008],[@pone.0237186.ref009]\]. Explicit methods, are focused on drugs (e.g., Beers and STOPP/START criteria), measuring how they fit to a set of predefined criteria \[[@pone.0237186.ref010]--[@pone.0237186.ref012]\]. These criteria are updated according to the available evidence for each different drug catalogues (USA or Europe). The implicit criteria are based on the global assessment by a health professional (pharmacist, internist, geriatrician or primary care physician), which takes into account the overall situation of the patient and whether the prescription corresponds to an indication or need. The most accepted implicit method internationally is the medication appropriateness index (MAI) \[[@pone.0237186.ref013]\].

Depending in the criteria used, the prevalence of patients with PIP differs significantly depending on the tools and the populations analysed (hospitalized, institutionalized or community patients) \[[@pone.0237186.ref014],[@pone.0237186.ref015]\]. It ranges from 40.4% detected using STOPP criteria \[[@pone.0237186.ref016]\] to 98.7% of prevalence using MAI criteria in primary care young elderly patients taking at least 5 drugs \[[@pone.0237186.ref017]\]. In Spain, the MAI has been evaluated in hospitalised patients \[[@pone.0237186.ref018]\] and has also been adapted and validated for primary care \[[@pone.0237186.ref019]\]. However, we still lack in young-elderly population studies in primary care patients complaining with multimorbidity and polypharmacy.

The association between explicit methods (STOPP or Beers) and implicit methods (MAI) in the primary care population has been investigated \[[@pone.0237186.ref020]\]. Recently, a study was published comparing the sensitivity and specificity of these three methods performed by two pharmacists, using the MAI as the *gold standard*, in a population from Kuwait. This study compared Beers 2015, STOPP 2014 and FORTA with the MAI, obtaining *kappa values* of 0.16 (p \<0.001), 0.40 (p \<0.001) and 0.23 (p \<0.001), respectively \[[@pone.0237186.ref021]\]. The most updated version of Beers 2019 has not been compared with the rest of the criteria.

Studies have shown association of high prevalence of PIP with worse health outcomes in patients such as unscheduled outpatient visits, emergency room visits, adverse events \[[@pone.0237186.ref017],[@pone.0237186.ref022]--[@pone.0237186.ref024]\], and hospital admissions and re-admissions \[[@pone.0237186.ref025]--[@pone.0237186.ref028]\]. Furthermore, this association has also been found when analysing patient reported outcomes (PROMs), such as quality of life (EQ-5D-3L) \[[@pone.0237186.ref029]\].

In an attempt to facilitate the detection of PIP in patients, in recent years, explicit criteria (STOPP and Beers) have been automated into computerized prescription assistance systems(CPAS) \[[@pone.0237186.ref030]\]. The translation of explicit criteria to computer algorithms is complex \[[@pone.0237186.ref031],[@pone.0237186.ref032]\] although easier than programming the implicit criteria (MAI) to computer pre-sets. The MAI criteria imply evaluating ten different aspects of each drug including indication, dose, effectiveness, interactions and duration, among others. Some of this evaluations even require health professional confirmation making this implicit criteria time consuming \[[@pone.0237186.ref013],[@pone.0237186.ref033]--[@pone.0237186.ref035]\].

The main aim of this study was to estimate the prevalence of PIP in a population aged 65 to 74 years with multimorbidity and polypharmacy, according to explicit criteria (Beers 2015 and 2019, STOPP 2008 and 2014); and implicit criteria (Medication appropriateness index--MAI-) in primary care. The secondary objectives were to assess the clinical and socio-demographic predictors for PIP and to compare these criteria in order to detect PIP with greater applicability to the Spanish population.

Material and methods {#sec007}
====================

The project has been favourably evaluated by the Central Committee of Primary Care Research of the Community of Madrid, the Commission for Health Research of the Aragon Institute for Health Research (IIS Aragon), and the Commission for Health Research of the Bio-Sanitary Research Institute in Malaga (IBIMA). The trial protocol was approved by the Clinical Research Ethics Committee of Aragon (CEICA) on September 30, 2015 (CP14/2015), and by the Research Ethics Committee of the Province of Malaga on September 25, 2015. Participant provided written consent to participate in the Multi-PAP trial Clinicaltrials.gov [NCT02866799](https://clinicaltrials.gov/ct2/show/NCT02866799).

Design {#sec008}
------

This was a cross-sectional, descriptive, multicentric, observational study conducted in the Spanish primary care setting.

Participants and setting {#sec009}
------------------------

Patients aged 65 to 74 years with multimorbidity (≥ 3 diseases) and polypharmacy (≥ 5 prescriptions taken for at least 3 months), who had attended their doctor consultation at least once over the last year and provided written consent to participate in the Multi-PAP trial Clinicaltrials.gov NCT02866799 were included \[[@pone.0237186.ref036]\]. Institutionalized patients, those whose life expectancy was \<12 months, as estimated by their doctor, and patients with any severe mental disorder were excluded. For physicians, the inclusion criterion was at least one year in their job. Presentations of the Multi-PAP project were held in health centres, and professionals were offered the chance to participate. One hundred and seventeen family doctors from 38 healthcare centres from three Spanish regions (Andalucia, Aragon, and Madrid) and 593 patients agreed to participate. For the proposed objective and based on previous studies in a similar population reporting an average MAI summated score of 15.8 (10.1 SD) \[[@pone.0237186.ref017]\], with this sample size and a design effect of 1.2, a maximum type I error of 0.975% with a 95% confidence interval (95%CI) was determined.

Data collection {#sec010}
---------------

Sociodemographic and clinical data were obtained during the period of patient recruitment in the MULTIPAP study, which was conducted between December 2016 and January 2017 through an interview with each patient\'s family doctor.

The method of collecting data on patients and doctors was not the same. Data on professionals (age, sex, length of physician career, and being postgraduate medical supervisor) were recorded by each physician in the data collection notebook after signing their commitment to collaborate in the study. Subsequently, sociodemographic and clinical data on patients were collected through an interview with each patient\'s general practitioner after signing the written informed consent.

Subsequently, the data were uploaded from the DCN into the CPAS ChecktheMeds^®^.

Variables {#sec011}
---------

The following socio-demographic variables were recorded for patients: age, sex, marital status, education level, social class according to the Spanish classification \[[@pone.0237186.ref037]\], and family income in thousands of euros adjusted by the number of people in the household (using the method proposed by the OECD Organisation for Economic Co-operation and Development). Additionally, the following clinical variables were collected: number of active pharmaceutical ingredients per patient according to the Anatomical, Therapeutic, Chemical (ATC) classification system; and chronic conditions in accordance with the international classification of primary care (ICPC), with the most relevant ones selected according to the criterion by O'Halloran \[[@pone.0237186.ref038]\]. The variables for the professional were age, sex, length of physician career, and being postgraduate medical supervisor.

Evaluation of prescribing appropriateness {#sec012}
-----------------------------------------

One researcher with broad clinical and therapeutic drug monitoring expertise supervised information transfer to the ChecktheMeds^®^ tool and used this tool to globally review the treatment of all patients. ChecktheMeds^®^ is a web-based tool to help health professionals for treatment plan review. It quickly analyses potentially inappropriate prescriptions, potentially drug-drug and drug-disease interactions, contraindications and adverse events. It takes into account clinical variables, diagnosis codes and the whole treatment of a patient. All collected data were supervised by a second reviewer. PIP was identified using the four explicit criteria selected and using one implicit criterion.

The explicit criteria were a) the 2019 Updated Beers criteria by the American Geriatric Society \[[@pone.0237186.ref011]\], b) the 2015 Beers criteria by the American Geriatrics Society \[[@pone.0237186.ref039]\], c) the 2014 v2 STOPP criteria \[[@pone.0237186.ref012]\], and d) the 2008 v1 STOPP criteria \[[@pone.0237186.ref040]\]. All the STOPP and Beers criteria were analysed. In agreement with former studies and to avoid potential information bias, this research team agreed on omitting the A1P STOPP criterion from the analysis (any drug prescribed but not indicated by clinical evidence) to prevent its overestimation \[[@pone.0237186.ref041]\]. START criteria assessing potential prescribing omissions were dismissed because the focus of this study was on already-prescribed inappropriate medications, instead of the need of starting new medications. The four criteria were automatically reported by the CPAS and compared.

The implicit criterion was the MAI \[[@pone.0237186.ref013]\], which includes 10 implicit criteria (indication, effectiveness, dosage, correct directions, practical directions, drug-drug interactions, drug-disease interaction, duplication, duration and expense). The MAI measures the suitability of each of a patient\'s drugs to these 10 criteria on a 3-grade Likert scale (A appropriate, C inappropriate). Only the "correct direction" criterion was omitted because this information was not able to be evaluated.

Each medication prescribed was rated by an independent family physician with pharmacological expertise for each Region, applying the usual weighted criteria (three raters in total). The raters were able to review the clinical history of the patients in the study to obtain as much information as possible. The drug-drug and drug-disease interactions were detected with the help of the CPAS ChecktheMeds^®^. A pilot rating of 17 different drugs (three patients) was carried out between the three raters using the same electronic health records and cases. Discrepancies were discussed until a consensus was reached. Additionally, a family physician and a pharmacist conducted a second appraisal of the inter-observer reliability over a randomly selected 10% of the completed questionnaires.

The MAI was evaluated by drug and by patient. The following were calculated: the percentage of drugs with at least one inappropriate criterion; the percentage of patients with at least one inappropriate criterion for any of the drugs \[[@pone.0237186.ref013]\]; the percentage of patients with a summated MAI of 3 or more \[[@pone.0237186.ref020]\]; and the summated MAI score per drug and per patient.

Statistical analysis {#sec013}
--------------------

Categorical variables are presented as frequencies and percentages. Quantitative variables are presented as the mean and standard deviation, with the corresponding CI 95% when the data fit a normal distribution or by the median and interquartile range (IQR) in the case of asymmetric data distribution. The MAI was used a reference point due to it's reliably and validity as a standardized assessment tool. For the gold standard test (MAI), a pilot rating for the level of absolute agreement across the three raters was evaluated using the intraclass correlation coefficient (ICC). Specificity and sensitivity of the explicit criteria were assessed using a contingency table, and confidence intervals were calculated using exact correction. Concordance between implicit and explicit criteria was estimated using kappa statistics. A multivariate linear regression model was developed to assess factors associated with the summated MAI score per patient (maximum of 18 points multiplied by each drug prescribed). The independent variables were those reaching statistical significance in the univariate analysis or considered of clinical relevance. Five different multivariate logistic regression models were built to determined factors that were independently associated with PIP, with robust estimators that controlled for the effect of cluster sampling. For each model, the dependent variable was constructed as follows: (I) being prescribed at least one PIP according to Beers 2019 criteria (0 = no, 1 = yes); (II) being prescribed at least one PIP according to Beers 2015 criteria (0 = no, 1 = yes); (III) being prescribed at least one PIP according to STOPP 2014 criteria (0 = no, 1 = yes); (IV) being prescribed at least one PIP according to STOPP 2008 criteria (0 = no, 1 = yes); and (V) being prescribed medication with one or more inappropriate rating in the MAI criteria (0 = summated patient score 0, 1 = summated patient score≥1) according to the original Hanlon definition \[[@pone.0237186.ref013]\]. Stata v14.0 software was employed for the statistical analyses.

Ethical approval {#sec014}
----------------

The MULTIPAP study was designed in accordance with the basic ethical principles of autonomy, beneficence, justice, and non-maleficence and was conducted in accordance with the rules of Good Clinical Practice outlined in the most recent Declaration of Helsinki and the Oviedo Convention (1997). Written informed consent of patients was required. Data confidentiality and anonymity was ensured, according to the provisions of Spanish Law 15/1999, both during the implementation phase of the project and in any resulting presentations or publications. The project has been favourably evaluated by the Central Committee of Primary Care Research of the Community of Madrid, the Commission for Health Research of the Aragon Institute for Health Research (IIS Aragon), and the Commission for Health Research of the Bio-Sanitary Research Institute in Malaga (IBIMA). It was approved by the Clinical Research Ethics Committee of Aragon (CEICA) on September 30, 2015, and by the Research Ethics Committee of the Province of Malaga on September 25, 2015.

Results {#sec015}
=======

Characteristics of the study participants {#sec016}
-----------------------------------------

A total of 4,386 prescriptions were rated for the 593 included patients. The mean age of the patients was 69.7 (2.7 SD) years, the age range was 65--74, 55.8% were women, 75.4% were married, and 17.9% lived alone. [Table 1](#pone.0237186.t001){ref-type="table"} provides the main socio-demographic and clinical characteristics of the patients and the professionals variables. Among chronic clinical conditions, 78.9% of patients had hypertension, and 50.8% hypercholesterolemia. The mean number of chronic conditions and medications per patient were 5.8 (2.3 SD) diseases and 7.4 (2.4 SD) prescriptions per patient. 17.9% of patients were prescribed ≥10 drugs ([Table 1](#pone.0237186.t001){ref-type="table"}).

10.1371/journal.pone.0237186.t001

###### Socio-demographic, clinical, and pharmacological characteristics of patients and physicians characteristic.
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  -------------------------------------------------------------------------------- ------------------------
  **Patient Characteristics (N = 593)**                                            
  Age, M (SD)                                                                      69.7 (2.7)
  Gender, n (%)                                                                    
   Female                                                                          331 (55.8)
   Male                                                                            262 (44.2)
  Nationality, n (%)                                                               
   Spanish                                                                         583 (98.3)
   Other                                                                           10 (1.7)
  Marital status, n (%)                                                            
  Single, divorced, widow                                                          146 (24.6)
  Married, living with couple                                                      447 (75.4)
  Living alone, n (%)                                                              106 (17.9)
  Educational level, n (%)                                                         
  Primary education not completed                                                  279 (47.0)
  Primary education                                                                196 (33.1)
  Secondary and superior education                                                 118 (19.9)
  Social class according to occupation, n (%)                                      
  Supervisors, managers, and directors                                             234 (39.5)
  Skilled primary sector                                                           217 (36.6)
  Unskilled                                                                        142 (23.9)
  **Patient Clinical Conditions**                                                  
  Number of chronic illnesses[\*](#t001fn001){ref-type="table-fn"}, median (IQR)   5.0 (4.0, 7.0)
  Most frequent chronic conditions,                                                n (%, 95% CI)
  High blood pressure                                                              468 (78.9; 75.6--82.2)
  Dyslipidemia                                                                     301 (50.8; 46.7--54.8)
  Diabetes                                                                         250 (43.3; 38.1--46.1)
  Osteoarthritis (knee, hand, hip and other)                                       225 (37.9; 34.0--41.9)
  Anxiety/Depression                                                               176 (29.7; 26.0--33.4)
  Hypothyroidism                                                                   113 (19.1; 15.9--22.2)
  Obesity                                                                          103 (17.4; 14.3--20.4)
  Benign Prostatic Hyperplasia (% over Men)                                        87 (33.2; 27.5--38.9)
  Ischemic heart disease                                                           101 (17.0; 14.0--20.1)
  Chronic heart failure                                                            21 (3.5; 2.0--5.0)
  Asthma                                                                           53 (8.9; 6.6--11.2)
  Chronic Obstructive Pulmonary Disease                                            64 (10.8; 8.3--13.3)
  Osteoporosis                                                                     75 (12.6; 10.0--15.3)
  Atrial Fibrillation/Flutter                                                      73 (12.3; 9.7--15.0)
  Esophageal diseases/peptic ulcers                                                50 (8.4; 6.2--10.7)s
  Number of drugs, median (IQR)                                                    7.0 (6.0, 9.0)
  5--6 drugs, n (%, CI)                                                            257 (43.3; 39.4--47.4)
  7--9 drugs, n (%, CI)                                                            230 (38.8; 34.9--42.8)
  ≥10 drugs, n (%, CI)                                                             106 (17.9; 15.0--21.2)
  **Physicians Characteristics (n = 117)**                                         
  Age, M (SD)                                                                      52.2 (6.8)
  Age Range                                                                        36--67
  Gender (women), n (%)                                                            77 (65.8)
  Average length of physician career, M (SD)                                       18.3 (3.4)
  Postgraduate Medical Education Trainers, n (%)                                   75 (64.1)
  -------------------------------------------------------------------------------- ------------------------

\*O\'Halloran list of Chronic Conditions for ICPC

M: Mean. [SD]{.ul}: Standard Deviation; IQR: Interquartile Range; CI: Confidence interval

For ATC groups, one of every three drugs (34.1%) prescribed belonged to the cardiovascular group, followed by metabolism and alimentary tract group and nervous system group. [Table 2](#pone.0237186.t002){ref-type="table"} shows the categories of drugs prescribed to patients according to ATC classification.

10.1371/journal.pone.0237186.t002

###### Anatomical therapeutics classification groups of drugs prescribed.
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  ATC         Group description                                                     N = 4,386 (%; 95% CI)
  ----------- --------------------------------------------------------------------- --------------------------
  *C Group*   Cardiovascular system                                                 1,494 (34.1; 32.7--35.5)
  *A Group*   Metabolism and alimentary tract                                       952 (21.7; 20.5--23.0)
  *N Group*   Nervous system                                                        879 (20.0; 18.9--21.3)
  *B Group*   Blood and Blood forming organs                                        392 (8.9; 8.1--9.8)
  *R Group*   Respiratory system                                                    248 (5.7; 5.0--6.4)
  *H Group*   Systemic hormonal preparations, excluding sex hormones and insulins   142 (3.2; 2.8--3.9)
  *M Group*   Musculo-skeletal system                                               141 (3.2; 2.7--3.9)
  *G Group*   Genito-urinary system and sex hormones                                112 (2.6; 2.1--3.1)
  *L Group*   Antineoplastic and immunomodulating agents                            26 (0.6; 0.4--0.9)

Inappropriate prescribing ratings {#sec017}
---------------------------------

The implicit criteria, the MAI, was evaluated for 4,386 prescriptions (589 patients). Four patients could not be evaluated due to not being able to access their medical records at the time of the evaluation. Moderate absolute agreement between the three raters was found, with an intraclass correlation coefficient of 0.41 (CI 95% 0.109--0.701). More than half of the prescriptions were considered appropriate (51.9%). The mean summated MAI score per drug was 1.4 (2.3 SD) (median 0; IQR 0--1). The mean summated MAI score per patient was 17.5 (16.8 SD) (median 14, IQR 5--25; range 0--102). Five hundred and fifty-four patients out of 589 had one or more inappropriate rating among their prescribed medications (94.1%). Of the 2,110 drugs considered inappropriate, 1,416 (67.1%) had less than three MAI inappropriate criteria ratings according to the Steinman classification \[[@pone.0237186.ref020]\], and 694 (32.9) met three or more MAI inappropriate criteria ratings. The MAI criteria with the highest inappropriate percentages were cost-effectiveness, duration, effectiveness and potential drug-drug interactions. [Table 3](#pone.0237186.t003){ref-type="table"} shows the distribution of inappropriate prescribing for each criterion. Omeprazole was the drug that accounted for the vast majority of inappropriate prescribing, having almost one in every five patients (19.9%) with an inappropriate MAI criterion rating. Additional information for the most common type of drug rated inappropriate can be found in [S1 Table](#pone.0237186.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0237186.t003

###### Distribution of inappropriate prescribing for each MAI criterion per drug prescribed or per patient.
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  Medication Appropriateness Index Criteria   Drugs with an inappropriate MAI criterion   Patients with an inappropriate MAI criterion in at least one medication
  ------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------
  Indication                                  430 (9.8; 9.0--10.7)                        285 (48.4; 44.3--52.4)
  Effectiveness                               724 (16.1; 15.4--17.3)                      385 (65.4; 61.5--69.2)
  Correct Dosage                              622 (14.2; 13.2--15.2)                      358 (60.8; 56.8--64.7)
  Correct Directions                          51 (1.2; 0.9--1.5)                          46 (7.8; 5.6--10.0)
  Practical Directions                        553 (12.6; 11.7--13.6)                      325 (55.1; 51.1--59.2)
  Potentially Drug-Drug Interaction           928 (21.2; 20.0--22.4)                      373 (63.3; 59.4--67.2)
  Drug-Disease/Condition interaction          421 (9.6; 8.8--10.5)                        178 (30.2; 26.5--34.0)
  Duplication                                 509 (11.6; 10.7--12.6)                      140 (23.8; 20.3--27.2)
  Duration                                    775 (17.7; 16.6--18.8)                      403 (68.4; 64.7--72.2)
  Cost-effectiveness                          979 (22.3; 21.1--23.6)                      427 (72.5; 68.9--76.1)

\*Medication Appropriateness Index

Based on the updated 2014 STOPP criteria, CPAS ChecktheMeds^®^ detected PIP (at least one explicit criterion) for 340 patients (57.4%), 83 more than with the 2008 version (43.3%) (see [Table 4](#pone.0237186.t004){ref-type="table"}). Eighty-two patients (13.8%) had 2 or more PIP with STOPP 2014 and 64 with STOPP 2008 (10.8%). The most frequently found PIP was the prolonged use of benzodiazepines (BZDs) for 217 patients (36.6%) using STOPP 2014 and 87 using STOPP 2008 (14.7%).

10.1371/journal.pone.0237186.t004

###### Sensitivity, specificity and measurements of agreements between different implicit and explicit criteria for appropriateness prescribing evaluation.
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                                       MAI[\*](#t004fn001){ref-type="table-fn"}   STOPP 2014            STOP 2008             Beers 2019             Beers 2015
  ------------------------------------ ------------------------------------------ --------------------- --------------------- ---------------------- ----------------------
  Prevalence of PIP (95% CI)           94.1% (92.1--96)                           57.4% (53.7--61.7)    43.3% (39.6--47.7)    68.8% (65.1--72.5)     70.8% (67.3--74.6)
  Sensitivity (95% CI)                 \-                                         60.1% (55.9--64.2)    45.3% (41.1--49.6)    68.8% (64.7--72.6)     71.8% (67.9--75.6)
  Specificity (95% CI)                 \-                                         80% (63.1--91.6)      82.9% (66.4--93.4)    31.4% (16.9--49.3)     42.9% (26.3--60.6)
  Positive Predictive Value (95% CI)   \-                                         97.9% (95.8--99.2)    97.7% (95--99.1)      94.1% (91.3--96.2)     95.2% (92.7--97.1)
  ROC area (95% CI)                    \-                                         0.7 (0.63;0.77)       0.64 (0.57;0.71)      0.5 (0.42;0.58)        0.57 (0.49;0.66)
  kappa index (p-value) (95% CI)       \-                                         0.104 (0.056;0.151)   0.057 (0.025;0.089)   0.001 (-0.052;0.054)   0.052 (-0.009;0.113)

\*Medication Appropriateness Index

More than two out of every three study participants (68.8%) met at least one of the 2019 updated Beers criteria, twelve less than when assessing the participants with the 2015 version (70.8%). For these patients, 197 (33.2%)had two or more PIP using Beers 2015 and 193 (30.6%) using Beers 2019. Applying the 2019 Beers criteria, the most frequent PIP was the prolonged used of proton-pump inhibitors (PPIs) by 260 patients (43.8%). This PIP is also the most frequent using Beers 2015 (45.4%).

Comparisons between the implicit criteria (gold standard) and updated explicit criteria {#sec018}
---------------------------------------------------------------------------------------

[Table 4](#pone.0237186.t004){ref-type="table"} shows the prevalence rates and the sensitivity and specificity for the two pair of versions of the explicit criteria comparing the old with the updated versions (STOPP 2008, STOPP 2014, Beers 2015 and Beers 2019) and comparing all of them with the implicit MAI criteria considered as the reference standard. A Venn diagram shows the agreement among the versions ([Fig 1](#pone.0237186.g001){ref-type="fig"}).

![Venn diagram.\
Agreement among the versions.](pone.0237186.g001){#pone.0237186.g001}

For the original version of the MAI, Beers 2015 had the highest sensitivity (71.8%) to detect PIP, followed by Beers 2019 (68.8%) and STOPP 2014 (60.1%). STOPP 2008 had the highest specificity (82.9%). The highest positive predictive value was obtained for STOPP 2014 (97.9%). The measurements of agreement (kappa indexes) were 0.104 between STOPP 2014 and the MAI, 0.057 between STOPP 2008 and the MAI and 0.001 between Beers 2019 and the MAI criteria.

There was no significant difference between the number of patients with PIP identified electronically by CPAS using Beers and STOPP criteria in their two more updated versions (p = 0.277). There were significant correlations between PIP identified by STOPP 2014 and the MAI (r = 0.192; p\<0.001), STOPP 2008 and the MAI (r = 0.185; p\<0.001) and Beers 2015 and the MAI (r = 0.311; p\<0.001). The highest correlation was found between STOPP 2014 and Beers 2015 (r = 0.358; p\<0.001) (correlation in [S2 Table](#pone.0237186.s002){ref-type="supplementary-material"}; the distribution of summated MAI score per number of explicit criteria can be found in [S3 Table](#pone.0237186.s003){ref-type="supplementary-material"}).

Factors independently associated with inappropriate prescribing based on implicit criteria and a comparison among explicit criteria methods {#sec019}
-------------------------------------------------------------------------------------------------------------------------------------------

Based on the multivariable linear regression analysis for the summated MAI score, diabetes, ischaemic heart disease and asthma were independently associated with lower summated MAI scores (see [Table 5](#pone.0237186.t005){ref-type="table"}). For every new drug taken by a patient, the MAI score increased by 2.41 (95% CI 1.46; 3.35) points. Out of all the physician factors studied, patients of doctors working also as postgraduate medical supervisors had lower MAI scores (coef. -5.52, 95% CI -9.60; -1.44).

10.1371/journal.pone.0237186.t005

###### Factors associated with summated medication appropriateness index scores.
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  INCREASING                                        Coefs.   CI 95%          p
  ------------------------------------------------- -------- --------------- ---------
  Number of drugs                                   2.41     1.46;3.35       \<0.001
  Usage of drugs in ATC A group (metabolism)        4.83     2.02;7.64       0.001
  Usage of drugs in ATC M group (musculoskeletal)   4.81     1.85;7.77       0.002
  Usage of drugs in ATC N group (nervous system)    3.31     0.87;5.74       0.008
  DECREASING                                                                 
  Diabetes                                          -6.29    -9.00; -3.58    \<0.001
  Ischaemic Heart Disease                           -6.92    -10.61; -3.23   \<0.001
  Asthma                                            -9.13    -12.59; -5.67   \<0.001
  Postgraduate Medical Education Trainers           -5.52    -9.60; -1.44    \<0.001

PIP: Potentially inappropriate prescription; Coef: Coefficients; CI: Confidence interval

ATC: Anatomical Therapeutic Chemical classification

Based on the multivariable logistic regressions performed for the MAI, STOPP and Beers criteria, taking more than 10 drugs was independently associated with inappropriate prescribing according to the MAI (OR: 20.86; 95% CI: 2.09;207.78, p = 0.010), STOPP 2014 criteria (OR: 4.96; 95% CI: 2.77;8.88, p\<0.001), STOPP 2008 criteria (OR: 7.88; 95% CI: 4.48;13.8, p\<0.001) and Beers 2015 criteria (OR: 3.31; 95% CI: 1.77;6.22, p\<0.001). This association was not found for the Beers 2019 criteria. Some of the clinical conditions were found to be related with inappropriate medication use, such as anxiety or depression, across the four main criteria or the presence of osteoarthritis (see [S4 Table](#pone.0237186.s004){ref-type="supplementary-material"}). [Fig 2](#pone.0237186.g002){ref-type="fig"} presents the estimated effects for different patient and physician characteristics for the two most sensitive explicit criteria compared to the MAI.

![Estimated effects for different patient and physician characteristics for the two most sensitive explicit criteria compared to the MAI.](pone.0237186.g002){#pone.0237186.g002}

Discussion {#sec020}
==========

Main findings {#sec021}
-------------

This study estimates, for the first time, the prevalence of PIP using the latest versions of explicit internationally accepted criteria and compares it with implicit criteria (MAI). The analysis of the criteria was performed by family doctors, with the help of a CPAS, for patients with multimorbidity and polypharmacy in primary care in Spain.

A total of 94.1% of the patients in this study had at least one criterion of inappropriateness for one of their drugs according to the MAI. PIP was detected in 57.7%, 43.6%, 68.8% and 71% of patients according to STOPP 2014, STOPP 2008, Beers 2019 and Beers 2015, respectively. Patients with more than 10 drugs had a significantly greater presence of inappropriateness using any of the four criteria. The MAI detected greater inappropriateness than did the explicit criteria. Using the MAI as the gold standard, the criteria with the highest sensitivity was Beers 2015; however, the highest positive predictive value was obtained with STOPP 2014, with better concordance measures to detect PIP compared with other versions of STOPP or Beers.

Prevalence of PIP {#sec022}
-----------------

### Implicit criteria {#sec023}

The prevalence of PIP varies according to the criteria used and the characteristics of the population and studies \[[@pone.0237186.ref014],[@pone.0237186.ref015],[@pone.0237186.ref042]\]. The mean score of the summated MAI score per drug was 1.4 (2.3), and the mean MAI score per patient was 17.5 (16.8). A total of 94.1% of the patients presented an inappropriate MAI criterion for a drug. These results were similar to those reported for a study conducted in the primary care setting in the United States with polymedicated patients aged\>65 years. This study detected PIP in 98.7% of patients and a summated MAI score per patient of 15.8 (10.1 SD) \[[@pone.0237186.ref017]\]. In another study in the primary care setting in Kuwait \[[@pone.0237186.ref021]\], the prevalence of PIP and mean MAI score were lower (PIP in 73.6% and MAI score per patient of 5.8 (5.8 SD)), but the population in this case had a mean consumption of drugs below that in our study. In a systematic review by Patterson et al. \[[@pone.0237186.ref043]\] of patients with polypharmacy aged over 65 years included in clinical trials from various areas, this score ranged from 6.5 to 19.3 in a total of 965 participants. In the PRIMUM trial \[[@pone.0237186.ref044]\], with a methodology and population similar to ours, the mean MAI was lower (4.6 (5.8 SD) in the control group and 4.8 (5.4 SD) in the intervention group). It is possible that the way in which the professional (pharmacist or doctor) evaluated patients with the MAI was not the same in the studies. The results will be different when the MAI is performed together with the patient, reviewing the clinical history (as in our study), or when only limited data are available from a DCN. There are some limited data regarding the summated MAI score in Spanish primary care population. Only data from palliative care patients in Spain \[[@pone.0237186.ref045]\] or primary care in France \[[@pone.0237186.ref018],[@pone.0237186.ref046]\].

The most frequent MAI individual criterion found in our study also differ from those found in the literature \[[@pone.0237186.ref017]\]. The item cost-effectiveness, the most frequent observed for our patients, could be biased due to the different prices of drugs in the different regions. This item has been eliminated in the adapted versions used in the studies that we previously indicated \[[@pone.0237186.ref021],[@pone.0237186.ref044]\]. The criterion "potential drug-drug interactions" was much more frequent in our work than in the previous studies \[[@pone.0237186.ref021]\]. This difference can be related to the support tools for the detection of interactions used by the rater. In our case, a CPAS was used that provides information from various sources in an automated manner; this may have helped to better detect interactions.

Language variations and different MAI-criteria weighting reduced the comparability of these studies and can explain the differences found.

### Explicit criteria {#sec024}

Using the Beers criteria, the prevalence was 68.8% and 70.8% for the 2019 and 2015 versions, respectively. To date, there are no data available to compare the latest versions (2015 and 2019). For the 2015 version, the data obtained is slightly higher than those reported by previous studies in a hospital population (53.5%) \[[@pone.0237186.ref047]\], and similar to studies conducted with insurance databases (72.8%) \[[@pone.0237186.ref014],[@pone.0237186.ref048]\]. With STOPP, this study obtained prevalence of 57.4% and 43.6% using STOPP 2014 and 2008, respectively, which is higher than those reported by prior studies \[[@pone.0237186.ref049],[@pone.0237186.ref050]\] using previous STOPP versions in the primary care setting and in the European population (36% and 39%, respectively). In those who used the 2014 version, the prevalence ranged between 8.7 and 40.4% \[[@pone.0237186.ref016],[@pone.0237186.ref041]\]; in a polymedicated geriatric primary care population in Kuwait, similar results were found (55.7%) \[[@pone.0237186.ref021]\]. The greater prevalence observed in this study could result from the included population, which had to meet the polypharmacy criterion to participate in the Multi-PAP trial, whereas only 72.9% or 72.1% of the patients in the abovementioned study were polymedicated.

Our results coincide with those of the majority of previous studies, placing BZDs and PPIs among the most frequently detected PIP with explicit criteria \[[@pone.0237186.ref014]--[@pone.0237186.ref016],[@pone.0237186.ref041],[@pone.0237186.ref049],[@pone.0237186.ref051]\]. The percentage of patients in our sample who used BZDs for more than four weeks (STOPP v2) was similar to that obtained by Blanco Reina \[[@pone.0237186.ref013]\] (36.6% vs. 38.6%). The prolonged use of PPIs was the PIP most frequently detected in our sample, with both Beers versions (2019 (43.8%) and 2015 (45.5%)). The Beers 2015 update included this criterion, and there are already authors who describe the prolonged use of PPIs as frequent \[[@pone.0237186.ref047]\], with 41.9%; however, the samples are not comparable to ours.

Comparison between implicit criteria and explicit criteria {#sec025}
----------------------------------------------------------

Taking the MAI as the gold standard, Beers 2015 had the highest sensitivity (71.8%) to detect PIP, followed by Beers 2019 (68.8%) and STOPP 2014 (60.1%). The highest positive predictive value was obtained using STOPP 2014 (97.9%). Our data differ from those obtained in the Kuwait study \[[@pone.0237186.ref021]\] in terms of the sensitivities obtained in the explicit criteria. However, given the characteristics of our population and the high prevalence of PIP, STOPP 2014 could have a better diagnostic yield by having a greater positive predictive value. In other words, when faced with a positive STOPP 2014 value, it would be more likely that PIP would actually be confirmed by the MAI in patients with multimorbidity and polypharmacy. This is especially relevant in populations with *a priori* suspicion of a high prevalence of inappropriateness. This differs from similar studies in which the median number of drugs was lower and the population was different \[[@pone.0237186.ref021]\].

In Steinman's study they found that patients with a MAI score of three or more points on any drug had a Beers criterion of 34%. In hospitalized patients, those with a Beers criterion at admission had a mean of 7.17 (0.11--14.23) summated-MAI score \[[@pone.0237186.ref052]\].

We obtained a higher prevalence of PIP with the MAI. These implicit criteria are potentially the most sensitive ones and can take into account patients' preferences. However, these methods are time-consuming and it requires intensive training and extensive knowledge \[[@pone.0237186.ref008],[@pone.0237186.ref020]\]. This means that they may not be the first option in clinical settings. Other tools, such as computer-automated explicit criteria, may be better options as an initial approach to determining the risk of drug inappropriateness.

It is evident that the common use measures of the quality of prescriptions produce widely discordant results (different quality metrics measuring different constructs). In studies comparing explicit methods with each other, the concordance among methods was low \[[@pone.0237186.ref016],[@pone.0237186.ref051],[@pone.0237186.ref053]\]. The different tools available can be complementary, and the decision to use one or the other should be related to the setting in which it is used and the purpose of its use. In research settings, a robust evaluation of the quality of prescriptions is probably necessary. However, in clinical practice, the use of explicit criteria, with less clinical detail and more easily automatable, can be applied more easily and quickly.

Factors associated with PIP {#sec026}
---------------------------

In this study, we found that diseases such as diabetes, ischaemic heart disease and asthma were significantly associated with a lower summated MAI score. It is possible that patients with these pathologies, which are well defined and delimited, with frequent and protocolled visits, are subjected to more follow-ups at which there is opportunity to properly review medication and to easily detect situations of drug inappropriateness. Patients of doctors working both, as family physicians and postgraduate medical supervisors, had lower summated MAI score. We have not found other studies that have reported similar results. This could be related to the greater training required for those working as supervisors and also because of increased awareness in terms of reviewing treatments for polymedicated patients. Additionally, there is a clear association between a greater number of drugs and the summated MAI score. Taking more than 10 drugs is associated independently with greater detection of PIP with explicit criteria and with the MAI. This result continues to make the cut-off of 10 drugs a possible proxy for complex multimorbidity and an important indicator of risk.

Conclusion {#sec027}
----------

In conclusion, the prevalence of PIP detected in the sample was high and in agreement with previous literature in young senior population with multimorbidity and polypharmacy. The MAI criteria detected greater inappropriateness than did the explicit criteria, but their application was more complex and difficult to automate.

Future studies should evaluate whether the application of implicit and explicit criteria with the help of automated tools by a professional alone, among others, could change the usual clinical practice and improve patient health.

Strengths and limitations {#sec028}
-------------------------

We found that this study covers an objective for which it was not initially designed. There was an attempt to partially correct this fact by estimating the aforementioned power as well as estimating the intervals with robust estimators to control the randomness introduced by the type of sampling. However, although the baseline information is trustworthy and was collected by each patient's doctor and verified, the MAI evaluation, which was performed by another external physician, was not performed with the patient in an interview but rather by reviewing each patient's medical history, which may have resulted in an inappropriate valuation of some criteria related to the perspectives of the patient and the prescribing physician that may not be included in medical records.

Among the strengths, it is noteworthy that this is the first Spanish study that automatically evaluated PIP with Beers 2019. It is also the first one comparing explicit and implicit criteria in its latest versions with the MAI. In addition, data collection through an interview with each patient\'s own doctor, the pragmatic design and an exhaustive review of each patient's clinical history by the raters confer reliability to the data in this work.

Future studies should evaluate whether the application of implicit and explicit criteria with the help of automated tools by a professional alone, among others, could change the usual clinical practice and improve patient health.

Supporting information {#sec029}
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\- Line 51: if you decide to include these cites, please, check how doing it.

Introduction: The contents of the introduction need to be related and exposed following a somewhat brighter argument line.

\- Line 66-67: please include the cite/s for this definition.

\- Lines 76, 97: the number must be before the \".\"

\- Line 96: Change "In our country..." by "In Spain..."

\- Line 97-98: Consider strengthening the rationale for this statement.

\- Line 99: Rewrite in a proper way mean and standard deviation.

\- Lines 99 to 106: Please, consider to examine this paragraph. It seems not clear enough. Something is missing in the last sentence.

\- Line 110, 112: Review the cite.

\- Lines 114-116: Please, consider to examine this paragraph. It seems not clear enough.

\- Line 124: Compare and concur the aim of the abstract and the introduction.

\- Lines 125-126: Review the cites.

Material and methods:

\- Line 148: the data were collected December 2016 -- January 2017? Have authors thought about include data from 2019 or 2020?

\- There were used the same method of data collection in patients and physicians? Please, clarify the method and variables for each group of participants.

Results

\- What is the range age of the patients?

\- Line 236: It is explained that "digestive system/metabolism" is one of the most popular group prescriptions, but in table 2, this group is identified as "metabolism and alimentary tract". Please, check and change this issue.

Discussion

-Line 349: The authors affirm the absence of studies with MAI quantitative data based on a 2013 article. Please check that the absence of evidence exists currently.

The conclusion section is missing.

Tables: check them and give the format according to the "Submission Guidelines".

Table 1: Complete with additional results (age range for patients & physicians, male gender, ...)

Table 3: Consider to remove column 1.

References: Check and make changes following the "Submission Guidelines".

Reviewer \#2: General comments

\- Pay attention to punctuation for instance in lines 76, 97.

Introduction

\- Lines 67-68, can the authors point to a reference to back up it?

Method

\- Why did you choose this inclusion criterion for the age of 74, for your study?

\- Delete line 141, "Participating physicians did not receive financial compensation".

\- Line 143: "from three Spanish regions ...", how were these regions selected? Based on which method?

\- Line 155: First time an abbreviation is used, the term should be spelled out in full.

Results

\- This section needs minor rectifications. Please consult with a statistician for how the section should be journalistic way written (lines 223-131).

Discussion

\- Line 343: delete (5 studies).

\- Lines 351 (... differ from those found in the literature.), 355 (... than in the previous studies): can the authors point to some reference to back up them?

Limitations

\- Line 427, delete (Among the main limitations) and then add all limitations of your study.

Also, please add "Conclusion" section and mention main findings of your study, implications.

\*\*\*\*\*\*\*\*\*\*

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Submitted filename: STROBE-cross-sectional_checklist-2.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0237186.r002

Author response to Decision Letter 0

21 May 2020

Response to reviewers

Reviewer \#1: Thank you for the opportunity to review this research work about the potentially inappropriate prescriptions in patients with multimorbidity and polypharmacy. I hope the following comments/ suggestions be useful in the development of this document.

I want to suggest it is needed to review the entire document by a native translator. The document needs changes that increase clarity and facilitate its reading.

Thank you very much for the suggestion regarding the language. We tried our best by translating and editing it by American Journal Expert. We attached the translation certification. We considered the American native speaker for the scope of this journal. We re-reviewed the translation and incorporated some changes to improve readability. Your suggestions have also been sent to AJE for clarification.

Title: Second part of the title could be more precise. Please, consider: "Potentially Inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy. MULTIPAP: A cross-sectional study."

We have incorporated your proposed title

Abstract: According to the "Submission Guidelines" the Abstract should not include citations and abbreviations, if possible. Please, check it.

\- Line 44: Multi-PAP is written in capitals in the title. Please, you should unify it. MULTIPAP has been corrected and unified.

\- Line 51: if you decide to include these cites, please, check how doing it.

All abbreviations have been checked and revised to include. The abbreviation Potentially Inappropriate Prescription (PIP) has been removed from the abstract. The Medication Appropriateness Index (MAI) has been maintained as it is the most common name for the questionnaire, as well as the STOPP criteria.

Introduction: The contents of the introduction need to be related and exposed following a somewhat brighter argument line.

\- Line 66-67: please include the cite/s for this definition. The reference has been included.

\- Lines 76, 97: the number must be before the \".\" The number has been placed before the \[ \]

\- Line 96: Change "In our country..." by "In Spain..." The change has been made.

\- Line 97-98: Consider strengthening the rationale for this statement. It has been deleted to simplify since it doesn't follow the narrative structure of the paragraph.

\- Line 99: Rewrite in a proper way mean and standard deviation. The change has been made.

\- Lines 99 to 106: Please, consider to examine this paragraph. It seems not clear enough. Something is missing in the last sentence. The paragraph has been revised and the acronym PC has been replaced throughout the text by primary care to make it more reader-friendly.

\- Line 110, 112: Review the cite. The cite has been revised.

\- Lines 114-116: Please, consider to examine this paragraph. It seems not clear enough. Paragraph has been restated to help understanding.

\- Line 124: Compare and concur the aim of the abstract and the introduction. The aims have been compared and their wording unified.

\- Lines 125-126: Review the cites. Lines 125 and 126 correspond to the wording of the objective, they do not contain cites.

Material and methods:

\- Line 148: the data were collected December 2016 -- January 2017? Have authors thought about include data from 2019 or 2020?

Sociodemographic and clinical data were obtained during the period of patient recruitment in the MULTIPAP study, which was conducted between December 2016 and January 2017 through an interview with each patient\'s family doctor. It is the baseline data of the study that are the object of interest of this work.

\- There were used the same method of data collection in patients and physicians? Please, clarify the method and variables for each group of participants.

The method of data collection on patients and physicians was not the same.

The method of collecting data on patients and doctors was not the same. Data on professionals (age, sex, length of physician career, and being postgraduate medical supervisor) were recorded by each physician in the data collection notebook after signing their commitment to collaborate in the study. Subsequently, sociodemographic and clinical data on patients were collected through an interview with each patient\'s general practitioner after signing the informed consent.

Results

\- What is the range age of the patients?

Since inclusion criteria were strict trying to look for "young seniors", the age range is exactly the same as the inclusion criteria, being 65-74 years old. For this reason we didn't include in the manuscript. Interquartile range was 68-72.

\- Line 236: It is explained that "digestive system/metabolism" is one of the most popular group prescriptions, but in table 2, this group is identified as "metabolism and alimentary tract". Please, check and change this issue.

The change has been made

Discussion

-Line 349: The authors affirm the absence of studies with MAI quantitative data based on a 2013 article. Please check that the absence of evidence exists currently.

We've reviewed the text and changed it to reflect what happens in the Spanish population. We included a more updated reference regarding the most alike population (French study by Gilbert). Citations has been included and updated.

The conclusion section is missing.

Following the sections proposed by the journal Plos one, Conclusions (optional) the section has not been included.

Following the reviewer\'s proposal, we have incorporated an epigraph "Implications of the study findings" synthesizing the conclusions. If you consider that a specific section of conclusions is more appropriate, we will proceed to do so.

Tables: check them and give the format according to the "Submission Guidelines". Reviewed

Table 1: Complete with additional results (age range for patients & physicians, male gender, ...) Included in the tables

Table 3: Consider to remove column 1.

We have removed column 1.

References: Check and make changes following the "Submission Guidelines". Cheked

 

Reviewer \#2: General comments

Pay attention to punctuation for instance in lines 76, 97.The number has been placed before the \[ \]

Introduction

\- Lines 67-68, can the authors point to a reference to back up it?. It has been pointed out since it's a shared comment with reviewer 1

Method

\- Why did you choose this inclusion criterion for the age of 74, for your study?

In Spain, in the context of the Strategy of the Ministry of Health, Social Policy and Equality to improve the care of polymedicated chronic patients, programs aimed at polymedicated elderly patients (\>75 years) have been implemented both nationally and in various regions. However, patients over 75 years old are only a part of the population with multi-morbidity. Patients who are sociologically define as young seniors (65-74 years old) have a high prevalence of multimorbility and polymedication and, although evidence on the effectiveness of interventions on this population group is even more limited, this is an age group with an important potential for early intervention. For this reason our study group focuses on this age range.

\- Delete line 141, "Participating physicians did not receive financial compensation". The line has been deleted

\- Line 143: "from three Spanish regions ...", how were these regions selected? Based on which method?

The three regions are Andalusia, Aragon and Madrid. They represent three regions geographically located in the south, centre and north of the country respectively. In each one, the Cooperative Research Network on Services and Chronic Diseases (REDISSEC) of the Carlos III Health Institute [www.redisecc.com](http://www.redisecc.com) has a research group with proven research experience on patients with multimorbility and chronic diseases. Our research approach both, the epidemiological perspective of the characterization of chronicity and the evaluation of the effectiveness of interventions in patients with chronic diseases in primary care.

These groups from the three regions obtained funding in competitive public calls for the MULTIPAP study, which includes cross-sectional studies such as the one proposed here, clinical trials, and cohort studies. www.multipap.es

\- Line 155: First time an abbreviation is used, the term should be spelled out in full. The term has been included in its complete form. The Organisation for Economic Co-operation and Development (OECD)

Results

\- This section needs minor rectifications. Please consult with a statistician for how the section should be journalistic way written (lines 223-131).

Several members of the research team are statisticians. We understand that you are referring to the wording of the paragraph in the lines (lines 223-231). Following your suggestions we have simplified the wording of the paragraph.

Discussion

\- Line 343: delete (5 studies). The words have been deleted

\- Lines 351 (... differ from those found in the literature.), 355 (... than in the previous studies): can the authors point to some reference to back up them?

The three citations supporting those statements have been relocated according to the specific section.

Limitations

\- Line 427, delete (Among the main limitations) and then add all limitations of your study.

"Among the main limitations" has been deleted

Also, please add "Conclusion" section and mention main findings of your study, implications.

Following the sections proposed by the journal Plos one, Conclusions (optional) the section has not been included.

Following the reviewer\'s proposal, we have incorporated an epigraph "Implications of the study findings" synthesizing the conclusions. If you consider that a specific section of conclusions is more appropriate, we will proceed to do so.
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Mojtaba Vaismoradi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

16 Jun 2020

PONE-D-20-04779R1

Potentially Inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy. MULTIPAP: A cross-sectional study

PLOS ONE

Dear Dr. ROGERO,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 31 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Prof, Mojtaba Vaismoradi, PhD, MScN, BScN

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer \#1: Dear author thanks for increasing manuscript quality with your efforts. Nevertheless, some of the changes suggested are missing yet.

Line 39-41: sample size has been removed from the abstract. Please, add it again.

Line 51-52: Add the bibliographic reference of each criterion: STOPP 2014, STOPP 2008, Beers 2019 & Beers 2015.

Introduction: I suggested in previous inform: \"The contents of the introduction need to be related and exposed following a somewhat brighter argument line\" and nothing has been done with this issue.

In response to reviewers, it is answered to my question about the method of data collection in patients and physicians. Please, include in the manuscript, in the same manner, the explanation given to reviewers.

Also, I would like to request again that be included the range age of patients in the results section, despite you explained it was an inclusion criteria.

Reviewer 2 and 1 agree with a conclusion section is needed in the manuscript. Please, consider to include it.

Reviewer \#2: The only challenge to the paper is that it needs a bit of editing for use of English grammar. With that editing I recommend publication.

Table 1: Substitute "Female, Male" instead of "Women, Men".

Lines 408-410: Grammar needs to be reviewed.

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237186.r004

Author response to Decision Letter 1

22 Jun 2020

Response to reviewers

Reviewer \#1: Dear author thanks for increasing manuscript quality with your efforts. Nevertheless, some of the changes suggested are missing yet.

Line 39-41: sample size has been removed from the abstract. Please, add it again.

Sample size has been included

Line 51-52: Add the bibliographic reference of each criterion: STOPP 2014, STOPP 2008, Beers 2019 & Beers 2015.

After reviewing journal style, Abstract section, along with other sections, does not accept bibliographic references. We understood, and after an editor consultation, that what was asked was to include acronyms definition for the abbreviations included in the abstract.

Introduction: I suggested in previous inform: \"The contents of the introduction need to be related and exposed following a somewhat brighter argument line\" and nothing has been done with this issue.

The argument line in the introduction has been changed

In response to reviewers, it is answered to my question about the method of data collection in patients and physicians. Please, include in the manuscript, in the same manner, the explanation given to reviewers.

The explanation given to the reviewers previously has been included in methods section.

Also, I would like to request again that be included the range age of patients in the results section, despite you explained it was an inclusion criteria.

The age range was already included in Table 1 and has been moved to results section as suggested.

Reviewer 2 and 1 agree with a conclusion section is needed in the manuscript. Please, consider to include it.

We have included the conclusions section

Reviewer \#2: The only challenge to the paper is that it needs a bit of editing for use of English grammar. With that editing I recommend publication.

Table 1: Substitute "Female, Male" instead of "Women, Men".

The change has been made

Lines 408-410: Grammar needs to be reviewed.

We have reviewed the grammar in these lines
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This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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PONE-D-20-04779R2

Potentially Inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy. MULTIPAP: A cross-sectional study

PLOS ONE

Dear Dr. ROGERO,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 29 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Prof, Mojtaba Vaismoradi, PhD, MScN, BScN

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer \#1: Dear author/s thanks for your efforts to increase manuscript quality. Now Introduction section\'s ideas are ordered following a line of argument that will enjoy the PLOS ONE readers. Thanks for taking into account all my last recommendations.

Nevertheless, a very minor change is needed.

Lines 40-42- In order to increase clarity, this is my suggestion: \"\[\...\] according to American Geriatrics Society Beers Criteria® (2015, 2019), the Screening Tool of Older Person's Prescription -STOPP- criteria (2008, 2014), and the Medication Appropriateness Index -MAI- criteria.\"

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237186.r006

Author response to Decision Letter 2

17 Jul 2020

Response to reviewers

Reviewer \#1:

Lines 40-42- In order to increase clarity, this is my suggestion: \"\[\...\] according to American Geriatrics Society Beers Criteria® (2015, 2019), the Screening Tool of Older Person's Prescription -STOPP- criteria (2008, 2014), and the Medication Appropriateness Index -MAI- criteria

The change has been made. It is true that it is clearer
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Dear Dr. ROGERO,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Prof, Mojtaba Vaismoradi, PhD, MScN, BScN

Academic Editor

PLOS ONE
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Dear Dr. Rogero-Blanco:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Mojtaba Vaismoradi

Academic Editor

PLOS ONE
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